Characterization of Recombinant Soluble Human Transforming Growth Factor-beta Receptor Type II (rhTGF-beta SRII)

Overview

Journal Cytokine

Specialties Allergy & Immunology
Biology

Date 1995 Jul 1

PMID 7578976

Citations 25

Authors

M L Tsang

L Zhou

B L Zheng

J Wenker

G Fransen

J Humphrey

J M Smith

M OConnor-McCourt

R Lucas

J A Weatherbee

Affiliations

Soon will be listed here.

Abstract

Recombinant human transforming growth factor soluble receptor Type II (rhTGF-beta sRII) corresponding to the 159 amino acid extracellular domain of hTGF-beta RII has been expressed in insect cells using the baculovirus expression system or in a mouse myeloma cell line. N-terminal sequence analysis of the purified protein revealed the removal of the 23 amino acid signal peptide. In SDS-PAGE, the rhTGF-beta sRII resolves into multiple bands due to N-linked glycosylation. Recombinant hTGF-beta sRII is a TGF-beta antagonist and will inhibit the biological activities of TGF-beta 1, TGF-beta 3, and TGF-beta 5 on TGF-beta-responsive cell lines, such as murine HT-2 or human TF-1 with an ED50 of approximately 0.3 micrograms/mL. However, hTGF-beta sRII does not inhibit TGF-beta 2 bioactivities in these cell lines, suggesting that hTGF-beta RII has low affinity for TGF-beta 2. Polyclonal antibodies to hTGF-beta sRII have been produced in goats and purified on Protein-G affinity columns. This antibody can inhibit TGF-beta 1,2,3,5-dependent bioactivities on human cell lines such as TF-1. Additionally, this antibody has species cross-reactivity and will also inhibit TGF-beta-dependent bioactivities on murine cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype.

Hall C, Law J, Reyat J, Cumberland M, Hang S, Vo N Sci Rep. 2023; 13(1):12137.

PMID: 37495732 PMC: 10372150. DOI: 10.1038/s41598-023-39369-y.

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.

Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y J Immunother Cancer. 2022; 10(12).

PMID: 36460337 PMC: 9723957. DOI: 10.1136/jitc-2022-005543.

Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All- Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation.

Phillips B, Garciafigueroa Y, Engman C, Liu W, Wang Y, Lakomy R Front Immunol. 2021; 12:586220.

PMID: 33763059 PMC: 7982719. DOI: 10.3389/fimmu.2021.586220.

Antigen Specificity Enhances Disease Control by Tregs in Vitiligo.

Mukhatayev Z, Dellacecca E, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K Front Immunol. 2020; 11:581433.

PMID: 33335528 PMC: 7736409. DOI: 10.3389/fimmu.2020.581433.

Receptor mimicking TGF-β1 binding peptide for targeting TGF-β1 signaling.

Belair D, Lee J, Kellner A, Huard J, Murphy W Biomater Sci. 2020; 9(3):645-652.

PMID: 33289741 PMC: 9254699. DOI: 10.1039/d0bm01374a.